Severe hypertriglyceridemia prevalence at a primary care setting in Catalonia, Spain

Ortega, Emilio; Vlacho, Bogdan; Treserres, Ray Puig; Mata-Cases, Manel; Altes, Andreu; Mauricio, Dídac; Franch-Nadal, Josep

doi:10.1016/j.jacl.2023.09.002

Journal of Clinical Lipidology

2023

DOI: 10.1016/j.jacl.2023.09.002

|View full text |Cite

Severe hypertriglyceridemia prevalence at a primary care setting in Catalonia, Spain

Emilio Ortega,

Bogdan Vlacho,

Ray Puig Treserres

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Pancreatic and cardiometabolic complications of severe hypertriglyceridaemia

Bashir,

Ferdousi,

Durrington

et al. 2024

Current Opinion in Lipidology

View full text Add to dashboard Cite

Purpose of review This review endeavours to explore the aetiopathogenesis and impact of severe hypertriglyceridemia (SHTG) and chylomicronaemia on cardiovascular, and pancreatic complications and summarizes the novel pharmacological options for management. Recent findings SHTG, although rare, presents significant diagnostic and therapeutic challenges. Familial chylomicronaemia syndrome (FCS), is the rare monogenic form of SHTG, associated with increased acute pancreatitis (AP) risk, whereas relatively common multifactorial chylomicronaemia syndrome (MCS) leans more towards cardiovascular complications. Despite the introduction and validation of the FCS Score, FCS continues to be underdiagnosed and diagnosis is often delayed. Longitudinal data on disease progression remains scant. SHTG-induced AP remains a life-threatening concern, with conservative treatment as the cornerstone while blood purification techniques offer limited additional benefit. Conventional lipid-lowering medications exhibit minimal efficacy, underscoring the growing interest in novel therapeutic avenues, that is, antisense oligonucleotides (ASO) and short interfering RNA (siRNA) targeting apolipoprotein C3 (ApoC3) and angiopoietin-like protein 3 and/or 8 (ANGPTL3/8). Summary Despite advancements in understanding the genetic basis and pathogenesis of SHTG, diagnostic and therapeutic challenges persist. The rarity of FCS and the heterogenous phenotype of MCS underscore the need for the development of predictive models for complications and tailored personalized treatment strategies. The establishment of national and international registries is advocated to augment disease comprehension and identify high-risk individuals.

show abstract

Pancreatic and cardiometabolic complications of severe hypertriglyceridaemia

Bashir,

Ferdousi,

Durrington

et al. 2024

Current Opinion in Lipidology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Severe hypertriglyceridemia prevalence at a primary care setting in Catalonia, Spain

Cited by 1 publication

References 36 publications

Pancreatic and cardiometabolic complications of severe hypertriglyceridaemia

Pancreatic and cardiometabolic complications of severe hypertriglyceridaemia

Contact Info

Product

Resources

About